Journal of the Pancreas Open Access

  • ISSN: 1590-8577
  • Journal h-index: 80
  • Journal CiteScore: 29.12
  • Journal Impact Factor: 19.45*
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +44 7460731551

Abstract

Detection of K-ras Point Mutation at Codon 12 in Pancreatic Diseases: A Study in a Brazilian Casuistic

Márcia Saldanha Kubrusly, José Eduardo Monteiro Cunha, Telésforo Bacchella, Emilio Elias Abdo, José Jukemura, Sonia Penteado, Cíntia Yoko Morioka, Lourenilson José de Souza, Marcel Cerqueira Cesar Machado

Objective To clarify the sensitivity and the validity of K- ras point mutational analysis at codon 12 in Brazilian patients with pancreatic diseases, and the possible correlation between the presence of the mutation and the histopathological findings. Patients Ninety-seven Brazilian patients with pancreatic ductal adenocarcinoma, pancreatic neuroendocrine tumors and chronic pancreatitis were enrolled in this study. Forty- five patients (46%) were female and 52 patients (54%) were male, having an average age of 60.2 ± 9.2 years for adenocarcinoma (n=52), 45.1 ± 19.4 years for pancreatic neuroendocrine tumors (n=20), and 46.4 ± 11.2 years for chronic pancreatitis (n=25). DNA extracted from 11 normal human peripheric lymphocytes was utilized as a control. Results The sensitivity of K- ras mutational analysis was 83.3% (25/30) in paraffin- embedded samples and 72.7% (16/22) in surgically resected specimens of the malignancy. On the other hand, no mutations were found in pancreatic neuroendocrine tumors or in chronic pancreatitis. Regarding the histopathological grading, the higher positivity rate was found in poorly- differentiated adenocarcinoma (100%), and progressively decreased in moderately- differentiated adenocarcinoma (72.2%), and well-differentiated adenocarcinoma (66.6%).The positivity rate in non-classified adenocarcinoma was 81.8%. Conclusion K- ras point mutation, in our study, is notably prevalent in malignancies and is absent in chronic pancreatitis and pancreatic neuroendocrine tumors. These results encourage us to consider the possibility of treatment strategies for this oncogene in the future.